Ana Galrinho
RadiologySurgeryCardiologyRetrospective cohort studySacubitril, ValsartanCardiac resynchronization therapyDilated cardiomyopathyMitral valveHeart failureCoronary artery diseaseAtrial fibrillationStenosisMitraClipPercutaneousPopulationMitral regurgitationMyocardial infarctionMedicineEjection fractionComplication
149Publications
9H-index
284Citations
Publications 150
Newest
Source
Source
BACKGROUND Sacubitril/valsartan had its prognosis benefit confirmed in the PARADIGM-HF trial. However, data on cardiopulmonary exercise testing (CPET) changes with sacubitril-valsartan therapy are scarce. OBJECTIVE This study aimed to compare CPET parameters before and after sacubitril-valsartan therapy. METHODS Prospective evaluation of chronic heart failure (HF) patients with left ventricular ejection fraction ≤40% despite optimized standard of care therapy, who started sacubitril-valsartan th...
1 CitationsSource
Background Assessment of 2D/3D left ventricular ejection fraction (LVEF) and 2D global longitudinal strain (GLS) is the gold standard for diagnosing cancer therapeutics-related cardiac dysfunction (CTRCD). Although 3D speckle-tracking echocardiography (STE) has several advantages, it is not used in this setting.
5 CitationsSource
AIMS: Myocardial work is a new transthoracic echocardiogram (TTE) parameter that enhances the information provided through left ventricular (LV) global longitudinal strain (GLS). Nothing is known about the impact of sacubitril/valsartan (LCZ696) therapy on myocardial work parameters. The aim of this study was to evaluate the effects of LCZ696 on LV myocardial work in heart failure patients. METHODS: Prospective evaluation of chronic heart failure patients with LV ejection fraction of 40% or less...
4 CitationsSource
Source
Source
Source
Source
12345678910
Close Researchers